☰

Angelina I. Londono-Joshi, Ph.D. - Publications

Affiliations: 
2013 Pathology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Pathology, Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 9: 19459. PMID 29721216 DOI: 10.18632/oncotarget.25151  0.598
2016 Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. PMID 27888804 DOI: 10.18632/Oncotarget.13466  0.718
2015 Che P, Yang Y, Han X, Hu M, Sellers JC, Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, Chen D, Li Q, Grizzle WE, Lu YY, Ding Q. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Scientific Reports. 5: 8453. PMID 25677816 DOI: 10.1038/Srep08453  0.637
2014 Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecologic Oncology. 134: 112-20. PMID 24736023 DOI: 10.1016/J.Ygyno.2014.04.005  0.661
2014 Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ. Effect of niclosamide on basal-like breast cancers. Molecular Cancer Therapeutics. 13: 800-11. PMID 24552774 DOI: 10.1158/1535-7163.Mct-13-0555  0.691
2014 Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM, Landen CN, Ferrone S, Buchsbaum DJ. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic Oncology. 132: 203-10. PMID 24216048 DOI: 10.1016/J.Ygyno.2013.10.038  0.643
2014 Haygood CLW, Arend RC, Londono-Joshi A, Kurpad C, Katre AA, Conner MG, Landen CN, Straughn JM, Buchsbaum DJ. Ovarian cancer ascites stem cell population compared to primary tumor Gynecologic Oncology. 133: 122. DOI: 10.1016/J.Ygyno.2014.03.320  0.632
2013 Arend RC, Londoño-Joshi AI, Straughn JM, Buchsbaum DJ. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecologic Oncology. 131: 772-9. PMID 24125749 DOI: 10.1016/J.Ygyno.2013.09.034  0.652
2013 Lin C, Lu W, Zhang W, Londoño-Joshi AI, Buchsbaum DJ, Bu G, Li Y. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells. Plos One. 8: e58102. PMID 23469146 DOI: 10.1371/Journal.Pone.0058102  0.565
2013 Swindall AF, Londoño-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Research. 73: 2368-78. PMID 23358684 DOI: 10.1158/0008-5472.Can-12-3424  0.624
2013 Londono-Joshi AI, Arend RC, Aristizabal L, Li Y, Lu W, Samant RS, Metge BJ, Forero A, Zhou T, LoBuglio AF, Buchsbaum DJ. Abstract 865: Inhibition of Wnt co-receptor LRP6 sensitizes basal-like breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody. Cancer Research. 73: 865-865. DOI: 10.1158/1538-7445.Am2013-865  0.699
2013 Arend RC, Londoño-Joshi AI, Li Y, Lu W, Samant RS, Metge BJ, Straughn JM, Buchsbaum DJ. Abstract 2179: Wnt pathway inhibition by niclosamide: a therapeutic target for ovarian cancer. Cancer Research. 73: 2179-2179. DOI: 10.1158/1538-7445.Am2013-2179  0.632
2012 Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM, Buchsbaum DJ. The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecologic Oncology. 125: 226-30. PMID 22155260 DOI: 10.1016/J.Ygyno.2011.12.425  0.596
2012 Londoño-Joshi AI, Oliver PG, Li Y, Lee CH, Forero-Torres A, LoBuglio AF, Buchsbaum DJ. Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Research and Treatment. 133: 437-45. PMID 21915634 DOI: 10.1007/S10549-011-1763-0  0.624
Show low-probability matches.